IL219325B - Compounds for targeting gadd45beta and uses thereof - Google Patents

Compounds for targeting gadd45beta and uses thereof

Info

Publication number
IL219325B
IL219325B IL219325A IL21932512A IL219325B IL 219325 B IL219325 B IL 219325B IL 219325 A IL219325 A IL 219325A IL 21932512 A IL21932512 A IL 21932512A IL 219325 B IL219325 B IL 219325B
Authority
IL
Israel
Prior art keywords
targeting compounds
gadd45 beta
gadd45
beta targeting
compounds
Prior art date
Application number
IL219325A
Other languages
English (en)
Hebrew (he)
Other versions
IL219325A0 (en
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of IL219325A0 publication Critical patent/IL219325A0/en
Publication of IL219325B publication Critical patent/IL219325B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL219325A 2009-10-22 2012-04-22 Compounds for targeting gadd45beta and uses thereof IL219325B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918579.4A GB0918579D0 (en) 2009-10-22 2009-10-22 Gadd45beta targeting agents
PCT/GB2010/001970 WO2011048390A2 (en) 2009-10-22 2010-10-22 Gadd45beta targeting agents

Publications (2)

Publication Number Publication Date
IL219325A0 IL219325A0 (en) 2012-06-28
IL219325B true IL219325B (en) 2019-02-28

Family

ID=41426579

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219325A IL219325B (en) 2009-10-22 2012-04-22 Compounds for targeting gadd45beta and uses thereof

Country Status (14)

Country Link
US (2) US8993717B2 (enExample)
EP (2) EP2491051A2 (enExample)
JP (2) JP5961113B2 (enExample)
KR (1) KR20120099440A (enExample)
CN (1) CN102741269B (enExample)
AU (1) AU2010309594B2 (enExample)
BR (1) BR112012011332B1 (enExample)
CA (2) CA3034860A1 (enExample)
GB (1) GB0918579D0 (enExample)
IL (1) IL219325B (enExample)
IN (1) IN2012DN03310A (enExample)
MX (1) MX357801B (enExample)
RU (2) RU2577311C2 (enExample)
WO (1) WO2011048390A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
KR101745766B1 (ko) * 2011-10-14 2017-06-09 서울대학교산학협력단 펩타이드 나노구조체 및 그 제조 방법
EP3777876B1 (en) * 2011-10-28 2023-08-09 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
GB201414542D0 (en) * 2014-08-15 2014-10-01 Imp Innovations Ltd Novel therapy
CN111606972B (zh) * 2019-01-30 2022-04-05 浙江省医学科学院 一种鳕鱼皮寡肽及其分离纯化和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
KR102348728B1 (ko) * 2020-03-23 2022-01-12 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
WO2021194228A1 (ko) * 2020-03-23 2021-09-30 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
WO2022203219A1 (ko) * 2021-03-22 2022-09-29 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
US20230159587A1 (en) * 2021-03-22 2023-05-25 L-Base Co., Ltd. Pharmaceutical composition for preventing or treating cancer
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
IT202100023357A1 (it) * 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
KR102786112B1 (ko) * 2021-09-17 2025-03-27 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
WO2023043261A1 (ko) * 2021-09-17 2023-03-23 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
KR102494749B1 (ko) * 2021-09-17 2023-02-06 주식회사 엘베이스 암 치료용 cage 저해제에 대한 반응자 특성화 방법
US20250213645A1 (en) * 2021-09-17 2025-07-03 L-Base Co., Ltd. Pharmaceutical composition for modulating immune response
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
CN116350746B (zh) * 2023-05-16 2024-03-22 海口桥水联合科技有限责任公司 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用
CN119874809A (zh) * 2025-01-13 2025-04-25 广东工业大学 一类抗氧化肽及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
HU187461B (en) * 1981-10-22 1986-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
DE3813989A1 (de) * 1987-04-29 1988-11-10 Hoechst Ag Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US20030162223A1 (en) * 1999-10-22 2003-08-28 Lowery David E. Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2447314A1 (en) * 2001-05-15 2002-11-21 Atsuro Nakazato Arginine derivatives
PT1790655E (pt) 2001-07-13 2010-07-09 Cms Peptides Patent Holding Co PéPTIDOS BIOLOGICAMENTE ACTIVOS
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
JP2006506975A (ja) 2002-08-19 2006-03-02 イェン、ユン 肝疾患の治療
EP1615954A2 (en) 2003-04-22 2006-01-18 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
ES2412483T3 (es) * 2005-01-13 2013-07-11 University Of Wollongong Derivados antibióticos de binaftilo
SI1853620T1 (sl) * 2005-02-09 2012-03-30 Helix Biomedix Inc Antimikrobni heksapeptidi
WO2006105811A1 (en) * 2005-04-07 2006-10-12 Centre National De La Recherche Scientifique Compounds useful as modulators of the proteasome activity
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7951782B2 (en) * 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
JP2007217358A (ja) * 2006-02-17 2007-08-30 Nippon Meat Packers Inc 抗酸化性ペプチド
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
CA2659655A1 (en) * 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
CN101153053B (zh) * 2006-09-28 2012-02-01 中国医学科学院药物研究所 骨生肽、其制备方法和其药物组合物与用途
EP1964560A1 (en) 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Use of inhibitors of the degradation of p27 for the treatment of cancer
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2390662A1 (en) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Molecular classification of multiple myeloma

Also Published As

Publication number Publication date
JP2016166211A (ja) 2016-09-15
EP2491051A2 (en) 2012-08-29
KR20120099440A (ko) 2012-09-10
WO2011048390A3 (en) 2011-11-03
US20150368294A1 (en) 2015-12-24
RU2016102083A (ru) 2018-11-20
EP3178836A1 (en) 2017-06-14
RU2577311C2 (ru) 2016-03-20
IN2012DN03310A (enExample) 2015-10-23
JP2013508346A (ja) 2013-03-07
CA2778236A1 (en) 2011-04-28
GB0918579D0 (en) 2009-12-09
BR112012011332B1 (pt) 2022-07-05
IL219325A0 (en) 2012-06-28
WO2011048390A2 (en) 2011-04-28
EP3178836B1 (en) 2019-12-25
US20120277164A1 (en) 2012-11-01
CA3034860A1 (en) 2011-04-28
CN102741269B (zh) 2017-08-29
US9518083B2 (en) 2016-12-13
JP5961113B2 (ja) 2016-08-02
MX2012004755A (es) 2012-11-22
BR112012011332A2 (pt) 2016-11-22
CN102741269A (zh) 2012-10-17
AU2010309594A1 (en) 2012-05-17
US8993717B2 (en) 2015-03-31
AU2010309594B2 (en) 2016-01-07
RU2012120905A (ru) 2013-11-27
MX357801B (es) 2018-07-25

Similar Documents

Publication Publication Date Title
IL219325B (en) Compounds for targeting gadd45beta and uses thereof
ZA201303499B (en) Specific diarylhydantoin and diarylthiohydantion compounds
AP3106A (en) Antiparisitic dihydroazole compounds and compositions comprising same
HUE068042T2 (hu) PSMA-targetáló vegyületek és alkalmazásaik
IL216973A0 (en) Heterocyclic compounds and their uses
IL218078A0 (en) Heterocyclic compounds and uses thereof
SG10201403696UA (en) Therapeutic compounds and compositions
IL219309A0 (en) Glycoside derivatives and uses thereof
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
SG173666A1 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
EP2464709A4 (en) MATERIALS DERIVED FROM CHRYSENE
EP2414481A4 (en) ELECTROACTIVE MATERIALS
ZA201107297B (en) Improved glucocorticoid thepary
IL214720A0 (en) Pyridocarbazole type compounds and applications thereof
ZA201200860B (en) New macrolides and their use
GB0902429D0 (en) Compositions and their use
GB0902173D0 (en) Compounds and their use
GB0909768D0 (en) Novel compounds and uses thereof
GB0922510D0 (en) Compound and use
SI2246181T1 (sl) Kompozitni material in njegova uporaba
GB0905525D0 (en) Compounds and uses
GB0909792D0 (en) Composition and uses thereof
PL387177A1 (pl) Związki enaminokarbonylowe i ich zastosowanie
GB0905231D0 (en) Compounds and their use
GB0902013D0 (en) Novel compounds and their use

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees